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Background: Nonpolypoid adenomas are a subgroup of colorectal adenomas that have been associated with a
more aggressive clinical behaviour compared to their polypoid counterparts. A substantial proportion of
nonpolypoid and polypoid adenomas lack APC mutations, APC methylation or chromosomal loss of the APC locus
on chromosome 5q, suggesting the involvement of other Wnt-pathway genes. The present study investigated
promoter methylation of several Wnt-pathway antagonists in both nonpolypoid and polypoid adenomas.
Methods: Quantitative methylation-specific PCR (qMSP) was used to evaluate methylation of four Wnt-antagonists,
SFRP2, WIF-1, DKK3 and SOX17 in 18 normal colorectal mucosa samples, 9 colorectal cancer cell lines, 18 carcinomas,
44 nonpolypoid and 44 polypoid adenomas. Results were integrated with previously obtained data on APC
mutation, methylation and chromosome 5q status from the same samples.
Results: Increased methylation of all genes was found in the majority of cell lines, adenomas and carcinomas
compared to normal controls. WIF-1 and DKK3 showed a significantly lower level of methylation in nonpolypoid
compared to polypoid adenomas (p < 0.01). Combining both adenoma types, a positive trend between APC
mutation and both WIF-1 and DKK3 methylation was observed (p < 0.05).
Conclusions: Methylation of Wnt-pathway antagonists represents an additional mechanism of constitutive
Wnt-pathway activation in colorectal adenomas. Current results further substantiate the existence of partially
alternative Wnt-pathway disruption mechanisms in nonpolypoid compared to polypoid adenomas, in line with
previous observations.
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Colorectal cancer (CRC) results from the accumulation
of multiple alterations in the (epi) genome of the epithe-
lial cells that line the large intestine. These events first
give rise to an adenoma that, in a minority of cases pro-
gresses into an invasive and potentially metastasizing
adenocarcinoma.
The terms polyp and adenoma have long been used as
synonyms. However, more recently it was recognized that
other phenotypes exist besides the traditional polypoid* Correspondence: b.carvalho@vumc.nl
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reproduction in any medium, provided the orcolorectal adenomas. Already in 1985 Muto et al. de-
scribed a lesion in the large intestine that was termed
‘small flat adenoma’ [1]. These nonpolypoid adenomas
were, until quite recently, considered rare in Western
countries. In Japan, on the other hand, they have been re-
ported to represent up to 40% of all colorectal adenomas
or early carcinomas [2,3]. Current studies in Western
countries, using advanced endoscopic imaging techniques,
have reported similar incidences of nonpolypoid lesions as
in the East [4-7]. Nonpolypoid lesions have been associ-
ated with a more aggressive behavior, are considered more
likely to contain advanced histology [7,8] and are expected
to have a different tumor biology [3,9].al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to carcinoma are the loss of tumor suppressor TP53, and
constitutive activation of KRAS and the Wnt-pathway [10].
Wnt-pathway activation represents a critical early event in
colorectal tumorigenesis and primarily results from inacti-
vating mutations in its gatekeeper APC [11,12]. Recently,
we found that nonpolypoid adenomas display less APC
mutations and simultaneously more frequent chromosome
5q loss (locus of APC) compared to polypoid adenomas
[13,14]. APC silencing by promoter hypermethylation
occurred at similar frequencies in both phenotypes
(Voorham et al., submitted). However, in a substantial
part of adenomas of both phenotypes no direct APC
disruption was observed. Next to activation of the
Wnt-signalling pathway via inactivation of the APC
gene (e.g. by mutation, deletion or hypermethylation),
methylation-mediated silencing of other upstream Wnt-
signal regulating genes may present an alternative mech-
anism of constitutive Wnt-pathway activation in CRC
[15,16]. Methylation plays an important role in CRC de-
velopment and many genes have altered methylation pat-
terns in the tumor compared to normal colon mucosa.
We aimed to investigate the contribution of methyla-
tion of a number of Wnt-regulators other than APC in
both nonpolypoid and polypoid adenomas. To this end,
four genes were selected known to have an antagonistic
effect on the Wnt-pathway, which have been described
before to be frequently methylated in CRC; Secreted
Frizzled-Related Protein-2 (SFRP2), Wnt Inhibitory
Factor-1 (WIF-1), Dickkopf-3 (DKK3) and SRY-Box-17
(SOX17) [17-24]. Promoter methylation of these four
genes was determined using quantitative methylation-
specific PCR (qMSP) [25] in a well-characterized series
of both nonpolypoid and polypoid adenomas, and find-
ings were related to previously obtained data on APC
mutation, APC promoter methylation and genomic loss
of the APC locus in the same adenomas.
Methods
Cell cultures
A panel of 9 CRC cell lines (Caco2, Colo205, Colo320,
HCT116, HT29, SW480, SW620, LS174T and LS513)
was used in this study. Colo205, Colo320, HCT116,
HT29, SW480, SW620, LS174T and LS513 were cul-
tured in DMEM (Lonza Biowhittaker, Verviers, Belgium)
supplemented with 10% fetal calf serum (FCS) (Hyclone,
Perbio, Etten-Leur, The Netherlands). Caco2 was cultured
in RPMI1640 (Lonza Biowhittaker) supplemented with
20% FCS. Both cell culture media were supplemented with
2 mM L-Glutamine, 100 IU/ml sodium-penicillin (Astellas
Pharma B.V., Leiderdorp, The Netherlands) and 100 μg/ml
streptomycin (Fisiopharma, Palomonta (SA), Italy). The
cervical cancer cell line CaSki was used as positive control
and cultured as described before [26]. All cell lines werecultured using coated flasks and dishes (Greiner Bio-One,
Frickenhausen, Germany).
Ethical statement
Collection, storage and use of archival tissue and patient
data were performed in compliance with the “Code for
Proper Secondary Use of Human Tissue in the Netherlands”
(http://www.fmwv.nl and www.federa.org). This study was
approved by the VU University medical center (2011-03),
the Leeds University (CA02/014 Leeds (West)) and the
Hospital Vitkovice (EK/140/10).
This study followed the ethical guidelines of the Insti-
tutional Review Board (IRB). The IRB waived the need
for consent for use of the archive samples, and the sam-
ples were analyzed anonymously.
Patient and sample selection
Formaldehyde-fixed, paraffin-embedded (FFPE) colorec-
tal tissue samples were collected at three different insti-
tutes; Leeds General Infirmary in Leeds, UK, Hospital
Vitkovice in Ostrava, Czech Republic and VU University
medical center in Amsterdam, The Netherlands [5,13,27].
Patients with a hereditary form of CRC, inflammatory
bowel disease were excluded. The final series contained 44
nonpolypoid adenomas, 44 polypoid adenomas and 18
carcinomas. Normal colorectal mucosa was collected from
age matched non-cancerous patients. Classification of the
adenomas was performed using the Paris classification
[28]. A summary of all clinical characteristics is listed in
Table 1.
DNA and RNA isolation
DNA and RNA from cell lines was isolated using TRIzol
Reagent (Life Technologies, Breda, The Netherlands) ac-
cording to the manufacturers’ instructions [29]. DNA
from FFPE material was isolated after macro-dissection
as described before [14].
Quantitative methylation specific PCR (qMSP)
DNA methylation analysis of SFRP2, WIF-1, DKK3 and
SOX17 was performed using quantitative methylation spe-
cific PCR (qMSP) as described before [25,30]. All samples
were tested in duplicate and average Ct values were used
for further analysis. Samples with delta Ct values between
duplicates more than 1.5 were excluded.
In addition, the modified, unmethylated sequence of
the housekeeping gene B-actin (ACTB) was amplified as
a reference to verify sufficient DNA quality and success-
ful DNA modification [31]. Samples with Ct-values > 32
for ACTB were excluded from further analysis. In all
qMSP runs, a negative (non-bilsulfite-treated cell line DNA
(CaSki)) and a positive (bisulfite-treated CaSki DNA) con-
trol were included. For all samples the delta Ct ratio be-
tween the gene of interest and ACTB was calculated using
Table 1 Clinical characteristics of the patients used in
this study
Normal
colorectal
mucosa
(n = 18)
Nonpolypoid
adenomas
(n = 44)
Polypoid
adenomas
(n = 44)
Carcinomas
(n = 18)
Gender M/F 6/12 24/20 22/22 8/10
Age (years) 71.33
(49-84)
70.77
(50-87)
70.98
(40-90)
71.50
(51-91)
Location
Left colon 14 40 7
Right colon 30 4 10
Size 17.30 (5-100) 19.39
(6-64)
N/A
Paris
classification
0-IIa 18
LST-G 7
LST-NG 19
0-Ip 44
Histology/
AC-stage
Tubular/B1 21 22 2
Tubulovillous/
B2
20 18 9
Villous/B3 2 4 1
Serrated/C2 1 5
C3 1
Dysplasia
Mild (LGD) 2 1
Moderate
(LGD)
38 36
Severe (HGD) 4 7
Chromosome
5q loss
8/38 1/30
APC methylation 34/41 29/44
APC mutation 16/44 26/44
Right colon includes caecum, ascending and transverse colon; Left colon
includes sigmoid, descending and splenic flexure; 0-IIa, slightly elevated
adenoma; LST-G, Granular lateral spreading type adenoma; LST-NG, Non-granular
lateral spreading type adenoma; 0-Ip, polypoid adenoma; AC-stage, Astler-Coller
stage; LGD, low grade dysplasia; HGD, high grade dysplasia.
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dence interval of normal controls was used as cut-off value
to determine methylation positivity. The reproducibility of
these assays has been demonstrated previously [25].
Relation between methylation and gene expression
CaSki cells were incubated with 0.2 and 5 μM 5-aza-2′-
deoxycytidine (DAC; Sigma Chemical Co, St Louis,
MO, USA) diluted in PBS for five days. All incuba-
tions were performed in duplicate, and cells weredirectly harvested for DNA and RNA isolation. Gene
expression was evaluated by RT-PCR as previously
described [30].
Statistical analysis
Statistical analysis was performed using SPSS 20. We
used a significance level of p < 0.013 (0.05/4 genes), to
adjust for multiple testing according to the correction
suggested by Bonferroni [33]. Comparisons between the
methylation levels in CRC cell lines and normal colon
were done using a non-parametric Mann-Whitney U
test. After that, a positivity score was performed using a
cut off level based on the upper limit of the 99% confi-
dence interval of the normal controls. All group compar-
isons were performed using two-sided chi-square or
Fisher exact test when expected values in the cross table
are below 10. In the overview tables it is indicated which
test was applied.
Logistic regression was used to examine the relation-
ship between WIF-1 methylation and the independent
variables phenotype, location, APC methylation, 5q loss
and APC mutation. First the univariate relationships be-
tween gene methylation and the dependent variables
were examined. Multivariate analyses were performed
including all variables with a univariate p-value of less
than 0.1. Next, we used a stepwise procedure and re-
moved the variable with the largest p-value in each step,
until only variables with a p-value < 0.05 remained in the
multivariate model.
Results
Promoter methylation in normal colon and CRC cell lines
Comparison of the SFRP2, WIF-1, DKK3 and SOX17
promoter methylation levels between nine CRC cell lines
and eighteen normal colon mucosa samples revealed
significantly elevated methylation levels in CRC cells
for all four genes (p = 0.00001, p = 3.1*10-5, p = 3.1*10-5
and p = 0.001 for SFRP2, WIF-1, DKK3 and SOX17,
respectively). For SFRP2, WIF-1 and DKK3 increased
methylation levels were observed in all nine CRC cell
lines, whereas SOX17 showed higher methylation levels in
all but two cell lines (LS513 and LS174T) (Figure 1).
Methylation lead to decreased expression, as upon
treatment with demethylating agents, an increase in ex-
pression was observed for SFRP2, DKK3 and SOX17 but
not for WIF-1 (Additional file 1: Figure S1).
Promoter methylation in carcinomas, polypoid and
nonpolypoid adenomas
Since the findings in cell lines are supportive of a role of
promotor methylation of these genes in colorectal car-
cinogenesis, we next investigated a series of tissue speci-
mens consisting of 18 carcinomas, 44 nonpolypoid and
44 polypoid adenomas.
Figure 1 Promoter methylation status in normal colon mucosa and in colorectal cancer cell lines. Scatter plots of the levels of SFRP2, WIF-1,
DKK3, SOX17 methylation. On the y-axes levels of DNA methylation are shown. The median is indicated with a black line. Asterisks indicate a statistical
significant difference.
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detectable in all carcinomas and in both polypoid and
nonpolypoid adenomas (Figure 2).
Interestingly, methylation levels in nonpolypoid aden-
omas were more similar to those observed in carcinomas
than those in polypoid adenomas. No relation in methy-
lation levels of any of the four genes and the different
carcinoma stages was observed (data not shown).
To dichotomize the qMSP results into positive or
negative for methylation, a cut off was calculated for
each gene based on the 99% confidence interval of the
normal controls (Figure 3). Significantly increased posi-
tivity rates were observed for all four genes in both types
of adenomas and in carcinomas compared to normal
colorectal mucosa (p < 0.003, Additional file 2: Table S1).
Interestingly, DKK3 and WIF-1 methylation frequencies
were significantly higher in polypoid adenomas (DKK3;
97% (38/39), WIF-1; 87% (34/39)) compared to nonpoly-
poid adenomas (DKK3; 76% (32/42), WIF-1; 57% (24/42);
p = 0.005 and p = 0.003, respectively). WIF-1 methylation
was also significantly higher in polypoid adenomas com-
pared to carcinomas (WIF-1; 47% (8/17), p = 0.003).
When the methylation results of the four Wnt-antagonists
were combined into one value that was positive if all
four markers were methylated 79% (31/39) of the polyp-
oid adenomas were positive in comparison to only 40%
(16/40) of the nonpolypoid adenomas (p = 0.0004), indi-
cating a lower level of Wnt-antagonist methylation in
nonpolypoid adenomas in general (Figure 3, Additional
file 2: Table S1).Promoter methylation in relation to anatomical location
To investigate the relation between methylation of SFRP2,
WIF-1, DKK3 and SOX17 and the anatomical location of
the adenoma, we divided all the adenomas into left- and
right-sided adenomas. This showed no statistical differ-
ence for the investigated genes, except for WIF-1 methyla-
tion, which showed more methylation in the left colon
82% (40/49) compared to the right colon 56% (18/32),
p = 0.01 (Table 2).
Promoter methylation combined with other molecular
events
Methylation of the Wnt-antagonists may provide an al-
ternative mechanism of Wnt-pathway activation next to
APC mutations, methylation and loss of the APC locus
on chromosome 5q. Therefore, we combined the pro-
moter methylation results for SFRP2, WIF-1, DKK3 and
SOX17, in polypoid and nonpolypoid adenomas, with
previously obtained molecular data on APC mutation
[13], APC methylation (Voorham et al., submitted) and
chromosome 5q loss [14] in the same samples. For APC
methylation as well as for chromosome 5q loss, no rela-
tion was found with the promoter methylation results for
SFRP2, WIF-1, DKK3 and SOX17 when combining both
adenomas types or in nonpolypoid adenomas or polypoid
adenomas, separately (Tables 3 and 4). For APC mutation,
a positive trend with WIF-1 as well as with DKK3 methy-
lation was observed (Table 5). Of the APC mutated aden-
omas 83% (33/40) showed WIF-1 methylation and of the
APC wild type adenomas 61% (25/41) showed WIF-1
Figure 2 Promoter methylation status in normal colon mucosa and different lesion types. Scatter plots of the levels of SFRP2, WIF-1, DKK3,
SOX17 methylation. On the y-axis levels of DNA methylation are shown; On the x-axis normal colon mucosa (NC-M), nonpolypoid adenomas
(NP-A), polypoid adenomas (P-A) and carcinomas (C) are indicated. The dotted line indicates the methylation cut off value based on the 99% CI
of normal colorectal mucosa. Asterisks indicate a statistical significant difference.
Voorham et al. BMC Cancer 2013, 13:603 Page 5 of 9
http://www.biomedcentral.com/1471-2407/13/603methylation (p = 0.048). For DKK3, 95% (38/40) of the
APC mutated samples showed DKK3methylation whereas
only 78% (32/41) showed DKK3 methylation in the APC
wild type adenomas (p = 0.026) (Table 5). When we com-
bined APC methylation, APC mutation and chromosome
5q loss together into one value called APC disruptingevent, no significant difference was found (Additional
file 2: Table S2).
Multivariate analyses
To investigate the possible interaction between the differ-
ent variables (phenotype, location, APC mutation, APC
Figure 3 Overview of DNA promoter methylation results of SFRP2, WIF-1, DKK3 and SOX17. Methylation results of SFRP2, WIF-1, DKK3 and
SOX17 are shown in relation to previous results on chromosome 5q loss [14], APC mutation [13] and APC methylation (Voorham et al. submitted)
in nonpolypoid and polypoid adenomas. Black box; event (methylation, 5q loss, APC mutation, White box; no event (no methylation, no
chromosome 5q loss, APC wild type), Grey box; no results.
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lysis was performed for WIF-1 methylation. For the genes
SFRP2, DKK3 and SOX17, we were unable to perform a
valid multivariate analysis, due to the limited number of
unmethylated samples[34].
For the WIF-1 gene, we first performed univariate ana-
lyses showing that phenotype (p-value = 0.004), location
(p-value = 0.016) and APC mutation (p = 0.035) were re-
lated to WIF-1 methylation. In the multivariate analysis,
location and APC mutation were removed from the
model (due to high p-values), leaving only phenotype in
the model. This suggests that phenotype is the major
contributor to the observed difference in WIF-1 methy-
lation in our samples.Table 2 Promoter methylation frequencies of SFRP2, WIF-1, D
Left nonpolypoid
adenomas
Right nonpolypoid
adenomas
p-value Left polypo
adenoma
SFRP2 79% (11/14) 100% (29/29) 0.3** 93% (37/4
WIF-1 69% (9/13) 52% (15/29) 0.3** 86% (31/3
DKK3 64% (9/14) 82% (23/28) 0.3** 97% (35/3
SOX17 86% (12/14) 97% (28/29) 0.2** 100% (36/3
All four
combined
38% (5/13) 41% (11/27) 0.9* 78% (28/3
Results are shown for polypoid adenomas, nonpolypoid adenomas and all adenom
All four combined; is considered positive if all four genes showed methylation. *chiDiscussion
The present study focussed on promoter methylation of
four known Wnt-pathway antagonists (SFRP2, WIF-1,
DKK3 and SOX17), in polypoid and nonpolypoid aden-
omas, and its possible association with other molecular
events that can play a role in Wnt-pathway activation.
All four Wnt-antagonists showed significant increased
methylation in CRC cell lines, carcinomas as well as in
nonpolypoid and polypoid adenomas compared to nor-
mal colon mucosa. A functional relation between methy-
lation and gene silencing was shown for SFRP2, DKK3
and SOX17.
To the best of our knowledge methylation of SFRP2,
DKK3 and SOX17 has not been described in nonpolypoidKK3 and SOX17 in relation to location
id
s
Right polypoid
adenomas
p-value All adenomas
left
All adenomas
right
p-value
0) 100% (4/4) 1** 89% (48/54) 100% (33/33) 0.08**
6) 100% (3/3) 1** 82% (40/49) 56% (18/32) 0.013*
6) 100% (3/3) 1** 88% (44/50) 84% (26/31) 0.7**
6) 100% (3/3) - 96% (48/50) 97% (31/32) 1**
6) 100% (3/3) 1** 67% (33/49) 47% (14/30) 0.07**
as together, divided into samples that were distal (left) or proximal (right).
-square based p-value **Fisher exact based p-value.
Table 3 Promoter methylation frequencies of SFRP2, WIF-1, DKK3 and SOX17 in relation with APC methylation
Nonpolypoid
APC methylated
Nonpolypoid
APC
unmethylated
p-value Polypoid APC
methylated
Polypoid APC
unmethylated
p-value All adenomas
APC methylated
All adenomas
APC
unmethylated
p-value
SFRP2 91% (30/33) 100% (7/7) 1** 93% (27/29) 93% (14/15) 1** 92% (57/62) 96% (21/22) 1**
WIF-1 59% (19/32) 43% (3/7) 0.7** 93% (22/25) 93% (12/14) 1** 71% (41/57) 68% (15/21) 1*
DKK3 72% (23/32) 86% (6/7) 0.7** 96% (24/25) 100% (14/14) 1** 83% (47/57) 96% (20/21) 0.3**
SOX17 91% (30/33) 100% (7/7) 1** 100% (25/25) 100% (14/14) - 95% (55/58) 100% (21/21) 0.6**
All four
combined
37% (11/30) 43% (3/7) 1** 80% (20/25) 79% (11/14) 1** 56% (31/55) 67% (14/21) 0.4*
Results are shown for polypoid adenomas, nonpolypoid adenomas and all adenomas together, divided into samples that were APC methylated or
APC unmethylated.
All four combined; is considered positive if all four genes showed methylation. *chi-square based p-value **Fisher exact based p-value.
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was described to be less frequent methylated in nonpoly-
poid lesions compared to polypoid ones [9,35].
The higher methylation of all four Wnt-antagonists in
CRC cell lines as well as carcinomas, compared to normal
colon mucosa, confirms current literature [17,19-23].
Interestingly, we found lower WIF-1 methylation fre-
quencies in carcinomas compared to polypoid adenomas
(WIF-1; 47% versus 87%) but not compared to nonpoly-
poid adenomas. Lower levels of methylation in carcin-
omas compared to adenomas have been described
before for WIF-1 [17] but also for other genes, such as
p14 [36] and ESR1 [17]. This may suggest that methyla-
tion of WIF-1 is less important in carcinomas or that
silencing of these genes in carcinomas is achieved by
other changes to the DNA [15]. We did not find a rela-
tion between methylation and mRNA expression for
WIF-1, indicating that WIF-1 gene expression might be
regulated by more complex regulatory mechanisms, po-
tentially including histone modification.
For DKK3 methylation a positive relation with higher
CRC stages was described [37]. This could not be
confirmed in our study, which may be explained by the
limited number of carcinomas investigated. For WIF-1
methylation no relation with CRC stage was observed by
either Aguilera et al. [37] or us.
Analysis of the relation of methylation of all four genes
with previously published results on APC disruptingTable 4 Promoter methylation frequencies of SFRP2, WIF-1, D
Nonpolypoid
5q loss
Nonpolypoid
no 5q loss
p-value Polypoid
5q loss
SFRP2 75% (6/8) 97% (28/29) 0.1** 100% (1/1)
WIF-1 50% (4/8) 60% (18/30) 0.7** 100% (1/1)
DKK3 63% (5/8) 82% (23/28) 0.3** 100% (1/1)
SOX17 88% (7/8) 97% (28/29) 0.4** 100% (1/1)
All four combined 25% (2/8) 43% (12/28) 0.4** 100% (1/1)
Results are shown for polypoid adenomas, nonpolypoid adenomas and all adenom
(locus of APC) or samples that had no chromosome 5q loss.
All four combined; is considered positive if all four genes showed methylation. **Fisevents (APC mutation, APC methylation and chromo-
some 5q loss, including the locus of APC) revealed a posi-
tive trend between WIF-1 and DKK3 methylation and
APC mutation. Although, the role of WIF-1 and DKK3
in the Wnt-signaling pathway is still poorly understood,
these data may suggest that methylation of these Wnt-
antagonists is complementing APC disruption and acts
synergistically [11,38].
Left and right CRCs have been suggested to be differ-
ent clinicopathological entities [39,40] Right CRCs occur
at an older age, predominantly in women and are char-
acterized by a high frequency of microsatellite instability
and hypermethylation, whereas left CRCs occur predom-
inantly in men and are characterized by chromosomal
instability [40]. A recent study revealed a (partly) distinct
methylation pattern in left- and right-sided adenomas
[41]. However, for some genes methylation levels were
higher in right-sided adenomas whereas for others methy-
lation levels were higher in left-sided adenomas. In the
current study we observed more frequent WIF-1 methyla-
tion in left-sided adenomas compared to right-sided aden-
omas. All other three genes were location-independent.
Next to the above mentioned observation that WIF-1
methylation was more frequent in adenomas from the left
colon, WIF-1 methylation was also higher in polypoid ad-
enomas compared to nonpolypoid adenomas. This could
introduce a bias in our analysis, since it is reported that
nonpolypoid adenomas occur more frequently in the rightKK3 and SOX17 in relation with chromosome 5q loss
Polypoid
no 5q loss
p-value All adenomas
5q loss
All adenomas
no 5q loss
p-value
90% (26/29) 1** 78% (7/9) 93% (54/58) 0.2**
92% (22/24) 1** 56% (5/9) 74% (40/54) 0.3**
96% (23/24) 1** 67% (6/9) 89% (46/52) 0.1**
100% (24/24) - 89% (8/9) 98% (52/53) 0.3**
66% (19/24) 1** 33% (3/9) 60% (31/52) 0.2**
as together, divided into samples that had a chromosome 5q loss
her exact based p-value.
Table 5 Promoter methylation frequencies of SFRP2, WIF-1, DKK3 and SOX17 in relation with APC mutation
Nonpolypoid
APC mutated
Nonpolypoid
APC WT
p-value Polypoid
APC mutated
Polypoid
APC WT
p-value All adenomas
APC mutated
All adenomas
APC WT
p-value
SFRP2 94% (15/16) 93% (25/27) 1** 89% (23/26) 100% (18/18) 0.3** 91% (38/42) 96% (43/45) 0.4**
WIF-1 63% (10/16) 54% (14/26) 0.6** 96% (23/24) 73% (11/15) 0.06** 83% (33/40) 61% (25/41) 0.03*
DKK3 88% (14/16) 69% (18/26) 0.3** 100% (24/24) 93% (14/15) 0.4** 95% (38/40) 78% (32/41) 0.03*
SOX17 94% (15/16) 93% (25/27) 1** 100% (24/24) 100% (15/15) - 98% (39/40) 95% (40/42) 1**
All four combined 50% (8/16) 33% (8/24) 0.3* 88% (21/24) 67% (10/15) 0.2** 73% (29/40) 46% (18/39) 0.017*
Results are shown for polypoid adenomas, nonpolypoid adenomas and all adenomas together, divided into samples that were APC mutated or APC wild type.
All four combined; is considered positive if all four genes showed methylation. *chi-square based p-value **Fisher exact based p-value.
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gate this, we performed a multivariate analysis including
phenotype and location but also APC mutation, APC
methylation and chromosome 5q loss. From this analysis
it became clear that phenotype was the main contributor
to the observed difference between polypoid and nonpoly-
poid adenomas.
In the current study we had to restrict our analysis to a
candidate gene approach, given the fact that the nonpoly-
poid adenomas studied are very small and concerned
FFPE material, as of which only a few methylation events
could be studied. A genome-wide methylation profiling
approach may reveal further distinctions between both
types of adenomas.
Conclusion
Methylation of SFRP2, WIF-1, DKK3 and SOX17 was
significantly higher in carcinomas as well as both types
of adenomas compared to normal colorectal mucosa.
We found higher levels of methylation for WIF-1 and
DKK3 in polypoid adenomas compared to nonpolypoid
adenomas. These results further substantiate differences
in Wnt-pathway disruption as already observed previ-
ously for APC mutation rate and APC loss in nonpoly-
poid adenomas compared to polypoid adenomas.Additional files
Additional file 1: Figure S1. DKK3, SFRP2 and SOX17 promoter
methylation is associated with reduced expression. We evaluated
whether SFRP2, WIF-1, DKK3 and SOX17 DNA methylation was inversely
correlated with its gene expression. It was shown before that all four
genes were methylated in CaSki cells [25] and therefore these cells were
treated with the methylation inhibitor DAC. QMSP analysis revealed high
levels of methylation of all four genes (panel A). Following DAC
treatment a clear decrease in methylation was seen for SFRP2, WIF-1 and
SOX17 and to a somewhat lesser extent for DKK3. As shown in panel B,
the decreased methylation after DAC treatment was correlated to an
increase in SFRP2, DKK3 and SOX17 mRNA expression. The housekeeping
gene SnRNP was used as control [30]. No effect on WIF-1 mRNA
expression was found after DAC treatment. Hence, methylation of SFRP2,
DKK3 and SOX17 affects its gene expression.
Additional file 2: Table S1. Promoter methylation frequencies of SFRP2,
WIF-1, DKK3 and SOX17 in polypoid adenomas, nonpolypoid adenomas
and carcinomas. Table S2. Promoter methylation frequencies of SFRP2,WIF-1, DKK3 and SOX17 in relation with an APC disrupting event. Results
are shown for all adenomas, divided into samples that harbor an APC
disrupting event or lack an APC disrupting event.
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